Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

Treating myeloma: the future is already here!

(2012) O. Landgren et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

(2011) N. Korde et al.   BLOOD

From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention

(2011) Ola Landgren et al.   CLINICAL CANCER RESEARCH

Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future

(2011) Ola Landgren et al.   SEMINARS IN HEMATOLOGY

Multiple Myeloma Precursor Disease

(2010) Ola Landgren et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD